Wordt geladen...
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
Opinion statement Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients’ response rate and survival; however, approximately one third of patients wit...
Bewaard in:
| Gepubliceerd in: | Curr Treat Options Oncol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5578701/ https://ncbi.nlm.nih.gov/pubmed/27193488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-016-0401-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|